- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.08. | Gilead dives into 'in vivo' cell therapy with $350M buyout of Interius | ||
| 21.08. | Sarepta pushes off debt payments in bid to regain financial footing | ||
| 20.08. | Xoma, a drug royalty specialist, buys another 'zombie' biotech | ||
| 20.08. | Lilly searching for new neuro chief as White set to retire | ||
| 20.08. | Rocket can resume gene therapy trial after FDA lifts hold | ||
| 20.08. | MAHA may take aim at pharma DTC ads | ||
| 19.08. | Viking shares sink as obesity pill misses expectations in key study | ||
| 19.08. | CSL to separate vaccine business, cut jobs | ||
| 19.08. | PTC Therapeutics drug for Friedrich's ataxia rejected; Lilly sells nearly $7B in bonds | ||
| 19.08. | Omega's Otello Stampacchia on the 'reset' changing biotech for the better | ||
| 18.08. | Stealth resubmits rare disease drug to FDA | ||
| 18.08. | Kennedy's mRNA cuts could set US science back, experts warn | ||
| 18.08. | Reunion's psychedelic drug headed to late-stage testing | ||
| 18.08. | Novo's Wegovy becomes first GLP-1 drug approved for MASH | ||
| 18.08. | The unexpected medication that could revolutionize the treatment of Alzheimer's disease | ||
| 18.08. | Navigating the oncology patent cliff: Strategic imperatives for big pharma | ||
| 15.08. | HHS revives defunct task force on childhood vaccine safety | ||
| 15.08. | Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial | ||
| 15.08. | Merck KGaA ventures into new territory in the US | ||
| 14.08. | Lilly says it will raise drug prices in Europe, responding to Trump threats | ||
| 14.08. | Sarepta sells Arrowhead shares as partnership, debt payments loom | ||
| 14.08. | Vedanta, PureTech's microbiome startup, to cut staff after study setback | ||
| 13.08. | Vor says drug licensed from RemeGen succeeded in Sjögren's study | ||
| 13.08. | AbbVie to build API plant in Illinois as it steps up US production | ||
| 12.08. | Insmed gains US approval of lung disease drug forecast to be blockbuster |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .